The study will test the drug ifetroban in patients who have completed cancer treatment for one of five cancer types and have no evidence of disease, but who are at very high risk for cancer recurrence.
Small cell lung cancer (SCLC) represents up to 25 percent of lung cancer cell deaths and is associated with early metastasis and poor patient survival.
A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
Recent studies have discovered a role for the transporter protein xCT in the survival of different cancer cell types including breast, glioma and lymphoma.
